Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Botswana
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States


This page was published on 07/06/2010
Published: 07/06/2010

  

Last Update: 07-06-2010  
Related category(ies):
Health & life sciences  |  Research policy

 

Add to PDF "basket"

EU study finds potential ES cells replacement falls short

In 2007, scientists discovered human induced pluripotent stem cells (iPS cells). Just like embryonic stem cells (ES cells), iPS cells can self-renew and turn into any kind of cell or tissue. The added advantage is that they carry almost none of the practical and ethical limitations that hinder ES cell research. A new study has found, however, that iPS cells do not have the same scope for use in some applications. The findings were presented at an event hosted by the ESTOOLS ('Platforms for biomedical discovery with human ES cells') project, which was funded EUR 12 million under the 'Life sciences, genomics and biotechnology for health' Thematic Area of the EU's Sixth Framework Programme (FP6).

Embryonic stem cells © Shutterstock
Embryonic stem cells
© Shutterstock

The landmark discovery of iPS cells signaled new hope for science. The key difference to ES cells is that the cells are obtained by genetically reprogramming an individual's somatic cells. By eliminating the concerns that surround the use of ES cells, iPS cells provide the opportunity for use in research and regenerative medicine and as models for diseases that cannot be easily studied in humans. Nevertheless, questions remain if iPS cells do in fact have the same application capacity as ES cells.

Results of a study conducted by the Hebrew University of Jerusalem in Israel (an ESTOOLS partner) and the Children’s Hospital Boston in the US suggest they are not able to entirely replace ES cells in some basic research and clinical applications.

The research findings were published in the May issue of Cell Stem Cell and presented in Lisbon, Portugal at the 'Stem Cells in Biology and Disease' International Symposium in May 2010. The symposium was organised by ESTOOLS, which represents the largest European consortium of researchers studying human embryonic stem cells (22 partners in total; 19 academic research institutes and 3 companies).

In the study, the team compared properties of iPS cells obtained from the skin cells of people affected by fragile X syndrome (the most common form of inherited mental impairment among males), with those of ES cells with the same genetic defect (isolated from embryos). They found that FMRI (the fragile X gene) was active in ES cells but not in iPS cells.

The lead author of the study, Hebrew University of Jerusalem's Dr Nissim Benvenisty, said: 'We saw a difference between iPS and embryonic stem cells, although they have the same mutation.' He noted that the results might underline a more general phenomenon of epigenetic differences between the two.

'Until we understand better the differences between these two types of cells, the optimal approach might be to model human genetic disorders using both systems, whenever possible,' Dr Benvenisty added.

Professor Peter Andrews from the University of Sheffield in the UK agreed that Dr Benvenisty's findings show that ES cells and iPS cells are complementary tools that in some cases may give different insights into fundamental disease processes. 'They emphasise the importance of continued research with both types of pluripotent human stem cells. The results also confirm the value and importance of European funding of research consortia like ESTOOLS,' Professor Andrews explained.

The ESTOOLS project is coordinated by the University of Sheffield. The symposium that took place between 26 and 28 May 2010 brought together international experts to exchange the latest advances in human stem cell research. The 'Third Ethics Workshop' was a parallel event, organised by ESTOOLS participant Göran Hermerén of the Lund University in Sweden and the European Group on Ethics in Science & New Technologies (EGE). A number of public outreach events also took place, including the play Staminalia, and the Smile of a Stem Cell photographic exhibition.


Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

ESTOOLS
Hebrew University of Jerusalem
Cell Stem Cell
'EU-funded study sheds light on DNA changes in human embryonic stem cells'





  Top   Research Information Center